CCO
Clear Channel Outdoor Holdings Inc
Mentions (24Hr)
0.00% Today
Reddit Posts
What does it mean when insiders sell?
Uranium Boom Idea | Anfield Energy (TSX.V: AEC) & Energy Fuels (NYSE: UUUU)
BlueFire Equipment Corp (BLFR) Acquires Screaming Eagle Partners, LLC, a Cashflow Positive Family-Owned Oil & Gas Company in Texas
Trading at 12.55% of Book Value on the NASDAQ at .34/share
And in the meantime the uranium price continues to increase + new urgent RFP coming in the market that will increase the upward pressure on the uranium price.
CCO breaking out today, now up over 20%
Communication Services Stocks Moving Up and Down Tuesday: GOGO, CCO, WIMI, CXDO, CNSL, EVER, FNGR, MSGM
What do y’all think about CCO? Seems promising
CCO - Clear Channel Outdoor Holdings - something to add to your radar
Medicinal Properties of Psychedelics With Psyched Wellness
A small overview about the latest news around the nuclear power restarts and the evolution in global uranium supply gap + latest information on a couple uranium companies
Uranium sector macro update: Multi-year uranium contracting cycle + the impact of the switch from underfeeding to overfeeding + the growing global uranium supply gap
Quick Look Into Psyched Wellness
Submitted an application for the AME-1 as a Natural Health Product to Health Canada: (CSE: $PSYC) Psyched Wellness
(CSE: $PSYC) Psyched Wellness - $7+ Billion Worldwide Mushroom Market by 2026
Movers at MidDay--$JFBR, $CCO, $QUOT, $CLOV
(CSE: $PSYC) Psyched Wellness - $7+ Billion Worldwide Mushroom Market by 2026
$TGODF/$TGOD Set to Merge with BZAM Cannabis to Create the Sixth Largest Canadian LP
What do you guys think about this Sweat Economy token. Walking can make money and is very beneficial for each individual's health
Psyched Wellness Analysis (CSE: $PSYC)
The uranium sector is evolving towards a growing global supply deficit, while the uranium price is still to cheap to incentivise new production + a couple uranium companies that have some catching up to do compared to peers
On Reg Sho Thresh hold List - Chart coiled and volume increasing. Tiny float, increasing revenues, management that can execute, ready to breakout $GROM
On Reg Sho Threshhold List - Chart coiled and volume increasing. Tiny float, increasing revenues, management that can execute, ready to breakout $GROM
On Reg Sho Threshhold List - Chart coiled and volume increasing. Tiny float, increasing revenues, management that can execute, ready to breakout $GROM
CCO, Clear Channel Outdoor Holdings looks promising this year
#126 - Building Cresco into the Industry's Partner of Choice (ft. Greg Butler, CCO of Cresco Labs) • by Cannabis Investing Network Podcast
PTPI — President & CCO Speaking at Bioconnect 2022 Conference January 10-13th
PTPI — President & CCO Speaking at Bioconnect 2022 Conference January 10-13th
SEAC🚀🦍🚀PTPI 🦍💎💎💎HOT. HOT HOT🔥🔥🔥☄️☄️💵💵💵💵💵💵
More Penny Stocks Getting Bought By Insiders - $SELB $OTLK $XOS $PED $HCDI
Institutional Holders and Stock Movements around Earnings
CCO great upside potential could be the next short squeeze. Currently, in a bull flag. see you at 20! 10/20 could be the day!
Why did The Coca-Cola Company choose KO as their symbol?
CCJ/CCO location map. Lots of great plays nearby
NXE on the TSX is just a cheaper CCJ/CCO, located next door
CCJ/CCO (cameco) location and other plays next door.
$ASTS: Universal 4k Porn streamed from anywhere on the planet Sea, Air, and Land!
$ASTS: Universal 4k Porn streamed from anywhere on the planet Sea, Air, and Land!
$ASTS The potential multibagger play in the making
TTCF - can't stop eating their products and buying their shares - why the stock is a long hold and will 6x ?
$XERS - An Undeserved Valuation: Xeris Pharmaceuticals
BNGO explode to $30 this month. Who is with me?
XXX APE OWNER OF $AMC --- Seeing huge volume spike (vs normal) on $CCO (Clear Channel Outdoor) - they are the ones that have supported our APE BILLBOARDS ALL AROUND COUNTRY
Great DD on XERS (Xeris Pharmaceuticals) which is just starting a short squeeze!
CCO: only way to go is up. In for 416 shares myself
CCO @ $2.43 👍🏼👍🏼🌞 Summer money
A couple of entertainment penny stocks to consider
MSNVF director just bought for 72 000$ in shares on the public market from his own pocket.
CCO Frank Hamlin and CFO James Bell are removed from GEE-EM-EE before 4Q release. Will probably impact price negatively because they're not replaced when things go well, but you just have to believe in the stock! Don't sell!
Why I’m short GME: EVP departures, secondary likely to follow 4Q print
Looks like Cohen is cleaning up shop “CCO leaving company”
GameStop CCO resigns ahead of Q4 earnings
GameStop CCO Franklin Hamlin to resign by end of March
GME CCO is resigning! More bullish news!
GME CCO is out - who’s the replacement
Good news Gorillionaires! Gamestop CCO is "resigning". Any bets on the replacement? (Remember to counter the downvotes).
Moon Tickets Still Available! | $XLPI Xcelplus International Inc. | Emerging Technology | Alternate Energy | Clean Energy | Waste to Energy | Now is the time to consider buying.
Moon Tickets Still Available! | $XLPI Xcelplus International Inc. | Emerging Technology | Alternate Energy | Clean Energy | Waste to Energy | Now is the time to consider buying.
[Quality DD] Xeris Pharmaceuticals is the most ridiculously undervalued pharma stock in the market right now.
Mentions
Funny how people can read the same documents but come to totally different conclusions. What I interpreted is that this confirms the CEO and the team are not mobile gaming people as they confirmed no desire to enter any regulated gaming markets (thus confirming why he backed out of WV making it very likely that they will have to pay out the 4.5 million dollar term fee plus legal costs. Also, if you look at Skillz they dominate the DFS space but still have the necessary regulatory structure in place so if VIPZ wants to be competitive to Skillz, which is less of a gaming company and more regulated payments + compliance moat type entity, VIPZ wouldn’t have given up the WV license. Which brings me to the fact that a gf of mine (who works in the industry) said that they heard from folks in TN that the compliance team left shortly after the new team came on board. She said they were very well respected so their departure speaks volumes of the current management/CEO and the likely deficiencies apparent in the CEO and the team which the opposite of what is needed in this very highly regulated space. Lastly, she says this space is likely to get regulated soon given the increased concern regarding responsible gaming (of any nature). If that does occur, to have a team without mobile gaming experience or even the desire to obtain/keep licenses is not a group I’d invest in as this is an inherently regulated space. Then add that the fact that the CFO, CCO and compliance team as a whole left right after the new CEO comes on board is either a coincidence or reflective of a much larger issue. I’m sure you’ll disagree but I had to put this out there so others don’t fall for this very biased hype of a very questionable penny stock. Happy investing to all.
U/nickman23 Cameco's money makers are MacArthur, Cigar Lake. The latter being the richest uranium deposit in the world. The operations in Nebraska and Rabbit are just a side show. Hell they shutdown rabbit for a number of years to manage supply. CCO.TO is the Canadian ticker for those who are curious. And yes, I think CCO.TO has a lot of upward movement ahead of it. The joint venture with Brookfield to buy Westinghouse is looking better and better every day.
URA, URNM, URNJ - all Uranium ETFs NXE, DNN, UUUU, CCO - great stocks to hold F3 Uranium, GLO - risky but attractive
CCO is usually a good bet depending on your timing. I’ve made money from calls and puts they have done well for me.
I bought some BEP and CCO is on my watchlist. With Cameco it's not what you're buying it's what your paying $$$
100% If you are buying options be prepared to exercise, if you are in shares hold until BO is announced and share price is close to BO value. The company doesn't have the staff to take the drugs to the market and is clearly positioned for M&A. They fired their sales team(CCO) and brought in Katherine Bach Kalin as an M&A expert. https://www.tipranks.com/news/the-fly/sellas-life-announces-departure-of-cco-francomano-general-counsel-wood
Except CCO is the Canadian ticker, which is showing the amount that should be USD. It’s scrambled beyond recognition.
Google finance is increasingly packed with errors. For instance, last two weeks, Cameco CCJ is missing. But then they weirdly started reporting it under the wrong ticker, the foreign one CCO.
MIST wtf - only thing I can see is the CCO gifting shares to a family member Could be a short attack too - guess we’ll find out soon enough
This is solid advice, definitely escalate with FINRA if you haven't already. The demand letter to their CCO is smart too since compliance officers hate having regulatory heat on them One thing I'd add - document everything with timestamps and keep records of every single interaction you've had with RH support. If this goes to arbitration you're gonna want a paper trail showing their pattern of just ignoring you for 18+ months
This is solid advice. FINRA complaints actually get results because these companies \*have\* to respond - it's not like emailing customer support and getting ghosted by a bot. And honestly at this point OP has all the leverage: no charges, property returned, police clearance letters. Robinhood has zero legal standing to keep that account frozen, they're just being lazy or hoping OP gives up. The demand letter to the CCO is key too. Once compliance knows there's a paper trail going to regulators, suddenly things start moving real fast.
# Future Catalysts Several **near-term catalysts** could impact Biofrontera’s stock: 1. **FDA Approval for Expanded Ameluz Indications**: Potential approval for **moderate-to-severe acne vulgaris** (Phase 2b completed, last patient out in August 2025) \[Simply Wall St, Aug 26, 2025\]. 2. **Phase 3 Trial Results**: Data readout for **actinic keratosis on extremities, neck, and trunk** (patient enrollment completed March 2025) \[Simply Wall St, Mar 18, 2025\]. 3. **Superficial Basal Cell Carcinoma (sBCC) Study**: Achievement of key milestone in Phase 3 PDT trial \[Simply Wall St, Jan 8, 2025\]. 4. **Reimbursement Improvements**: Enhanced insurance coverage could boost adoption. 5. **Resolution of Nasdaq Listing Issues**: A reverse stock split or capital raise may be needed to regain compliance. 6. **Commercial Execution**: Success in scaling sales under new CCO George Jones. These catalysts could drive **revenue growth and margin expansion**, but execution risk remains high.
Yes I had CCO at $27, sold half at 95, sold second half at $134 - then it hit 153…
Personally; my side bets can be described as western rare magnets (Neo Performance Materials for example) & Heavy Rare Earth. Robotics will take off and currently they all need similar materials irrespective of which companies producing them win for lack of a better word. For example one area I'm currently looking into is potential western production of PEEK as a material which is produced primarily from DFNB which China controls nearly all of. Separately I like KAP and CCO for uranium and have various other side bets for lack of a better word: space, water treatment etc
Edit: CEO and CCO bought shares today https://investor.sweetgreen.com/financials/sec-filings/default.aspx
Cameco is tied up with the AI boom. If AI stocks keep going up, CCO/CCJ does also. If the AI bubble pops, CCO will pop also. Perhaps not as much as core AI stocks and it will rebound faster, but it will crash initially (my guess is 50% range).
Nice to see CCO jump today. What else do you hold besides QNC in the quantum space?
Cant post good DD without a huge position, then ill do like bots and spam tickers BEP , BAM, CCO, TO THE MOOOOONNNN HAPPY NOW
Everyone talking fake meat and openAI, and here I was sitting with 20k in $CCO, freat little canadian uranium company! :D
CCO/CCJ making a recovery
Uranium is not mentioned in any of their financial statements, my friend. "The CCO said" to who? A gas station attendant? This feels like a squeeze play on the back end of BYND.
I prefer CCO and KAP, all in on the uranium:p
AI-Nuke bubble bust. Those startup SMR NNE, OKLO, SMR \~ -1/3 from highs The REAL nuke companies holding up better BWXT, GEV, CCO, CAT
CCO you sob, help me with my losses lol
anyone know what's up with the CCO pop?
Well they had a revenue of 600.000 dollar and a loss of nearly 30 million, in Q2… according to investing.com the Ceo and CCO sold a part of their stocks. They really need a big breakthrough.
Explain? Their CEO and CCO hate making money.
I have CCO and NXE in a 2:1 ratio. Thinking of ramping up NXE to match my Cameco holdings. The smartest thing to do would be just to grab one of the uranium ETFs probably (HURA in Canada).
I was buying CCO for $29 a share when I first entered the market in 2022. I wish I kept buying it monthly at DOC for the last 3 years.
Just asked the teacher, he doesn't want my portfolio to be too focused on one industry, and he wants me to focus more on the leadership vs actual gain. I have AAPL, NVDA, RHM, CCO, UBER, META, TSLA, JPM.
Can also add in some MGA but I'm adding CCO/J & NXE at a 2:1 ratio and buying in weekly.
I just read CCO Severance Agreement.
Gold and Uranium are on the run. Still Time to be in now. UEC, UUUU, SCZ, GLCC, CCO, AYA
Turned $250k CAD (March 2020) into ~$3.0M CAD by Aug 2025 (≈ $2.1M USD), a ~58% CAGR over ~5.4 years. Edge came from: timing (near the COVID bottom), concentrated conviction (mainly Cameco/CCO), very high savings rate (~90% of discretionary income), and staying invested.
Yes, I actually heard about this stock from some DD done on Wall Street bets funny enough. I rand the DD through chat GPT and it looks and give feed back. Chat GPT said the following... This is one of the better Reddit DD write-ups I’ve seen in a long time — not perfect, but it lays out a compelling high-conviction, risk-reward thesis on $IOVA. Let me give you a full take: --- 🧠 TL;DR: Is this legit? Yes. If you're hunting a deep-value biotech rebound with massive short interest, real FDA-approved product, and asymmetric upside — this thesis is strong. It's not hype alone — it’s anchored in facts. --- 🔬 Let’s break it down: ✅ 1. Replimune’s failure is a huge tailwind Replimune ($REPL) getting a complete response letter from the FDA basically eliminates IOVA’s biggest melanoma rival (for now). This opens up the playing field for Amtagvi to dominate late-stage melanoma. Wall Street underestimated this shift. The author nails this. ✅ 2. Real-world response data is stunning 49% overall response rate in multi-failure patients is genuinely impressive. 60.9% in early-line patients? That’s rare territory — this could lead to earlier-line approvals, dramatically increasing patient pool. $500K/treatment with insurance coverage? That’s real monetization of innovation. ✅ 3. Management shakeup is meaningful Adding a real CCO and CFO with track records from successful biotechs adds confidence. The company has faced execution issues in the past — the team refresh is part of the solution. ✅ 4. Short interest + low float = potential squeeze 34.5% short interest with over 80% institutional ownership = only scraps left for retail to trade. If this gets momentum, there might not be enough shares to cover, which is the fuel for a proper short squeeze. --- 🧨 Weak Spots in the Thesis Let’s be honest — even solid DD has blind spots. Here are the main ones: Risk Reality Execution risk remains New team or not, commercial rollout in biotech is hard. Bottlenecks still possible. Lawsuit over prior disclosures There is an active securities lawsuit underway — could weigh on sentiment. Biotech volatility Even with good news, these names whip around like crazy. You could see –30% days for no reason. $1B revenue forecast is aspirational They need to prove they can hit even $200M/yr before markets buy into $1B talk. Still — none of these flaws invalidate the thesis. They’re just risks to factor in if you size up a position. --- 🎯 Price Targets: Are $10–15 realistic? Yes, but only with two key conditions: 1. Q2 earnings (likely in August) must confirm a ramp in sales and demand 2. No major delays or bad guidance from management If those two go well, the squeeze + fundamental re-rating could absolutely push this to $10–12 short-term, and possibly $15+ if uptake goes parabolic by year-end. --- 📦 Position Strategy (if you buy in) Entry Zone: ~$3.00–3.30 Stop-Loss: Optional, but a mental stop around $2.25–2.50 is fair Profit Target 1: $6–7 Profit Target 2: $10+ Add trigger: Above $4.00 on volume with Q2 guidance beat You can always scale in — start with a half-size and build into strength or news. --- 🏁 Final Word The Reddit post is smart, well-researched, and genuinely bullish for good reason. It’s not hype for the sake of it — it’s grounded in improving data, market dynamics, and a rare biotech setup. If you’re open to high-risk, high-reward biotech with real catalysts and a ridiculous squeeze setup, this is honestly one of the best asymmetric setups in the market right now. Let me know if you want a quick technical chart readout or to set trade alerts for breakouts or volume spikes.
📊 AYTU – Superstock Checklist # Criterion Meets? Comments & Data 1 Price $1–$15 ✅ Yes $2.32 (July 16, 2025) 2 Breakout from strong base ✅ Yes Recent breakout after earnings, strong technical signals 3 Breakout above 30WMA ✅ Yes Price is well above 50- and 200-day MAs ($1.93 / $1.67) 4 Massive weekly volume ✅ Yes Typical: ~200k, recent spikes >1M (Finviz) 5 Steep angle of attack ✅ Yes Up 28% YTD, +34% after news; sharp move visible 6 Clean chart ✅ Yes Few gaps, clear uptrend since base 7 Prior momentum ✅ Yes Multi-month uptrend after strategic restructuring 8 Acts like a superstock (‘magic line’) ✅ Yes Outperforms other small-cap biotechs, clear breakout 9 EPS positive ✅ Yes Q3 FY25: $0.21; Q2 FY25: $0.13 10 Earnings sustainable ✅ Yes Revenue growth 2024–2025; recurring pharma income 11 P/E ≤ 10 ✅ Yes No standard P/E, forward P/S ~0.99; EV/EBITDA ~4 12 Sequential improvement ✅ Yes Q-on-Q improvement visible 13 Easy YoY comparison ✅ Yes +32% sales, +65% EBITDA YoY 14 High operating leverage ✅ Yes High margins, EBITDA >$600k on $18M sales (~22%) and growing 15 Increasing backlog ✅ Yes New contracts (EXXUA commercialization) show pipeline is growing 16 Insider buying? ✅ Yes CEO bought 15k shares @ $1.30; other officers also bought 17 Low float & market cap ✅ Yes ~$20M market cap, float ~6.7M shares 18 IT factor ✅ Yes Focus on ADHD/depression meds (EXXUA, Adzenys, etc.) 19 Conservative management ✅ Yes Strong cash, low debt/EBITDA ~2.9; refinancing April 2025 20 Simple headlines ✅ Yes “First-in-class antidepressant approved...” etc. 21 No listed options ❌ No Options available (Finviz) 22 Little/no competition ⚠️ Partial Biotech always has competition, but EXXUA is unique in its class 23 Low short interest (<20%) ✅ Yes Short interest very low (<5%) 24 Not highly leveraged ✅ Yes Debt/equity only 0.65 25 Not a commodity play ✅ Yes Pure pharma, no commodities exposure 26 IBD 100 ❌ No Not included 27 No analyst coverage ⚠️ Limited Lake Street covers it, but little mainstream coverage 28 Super traders on board ❌ No No large hedge funds or “supertrader” presence 29 Insider ownership 20–30% ✅ Yes Insiders/founders historically ~20%+ (CEO, CCO, etc.) 30 Long trading history, not recent IPO ✅ Yes Public since ~2015, no SPAC/recent IPO 31 Great ticker ✅ Yes “AYTU” is short, clear, and unique 📈 Score & Evaluation ✅ Fully met: 27 / 31 ⚠️ Partial: 22 (competition), 27 (analyst coverage), 16 (recent insider buys – present but not massive) ❌ Not met: 21 (options), 26 (IBD 100), 28 (supertraders) 🔍 Summary Aytu BioPharma is a very strong Superstock candidate per Jesse Stine’s method: ✔️ Profitable, breakout, high momentum ✔️ Low float, microcap, recurring revenue, strong new product (EXXUA) ✔️ Solid insider discipline, clear headlines, growing backlog ✔️ No commodity risk, low debt, minimal analyst/hype risk Risks: options exist, limited analyst coverage, biotech always has competition and event risk.
Buying BULL options is like donating to the CCO
I personally like CCO, KAP (both nuclear). Also Veolia Environment, Lion Finance Group and Pfizer
He should have been a CCO instead of CEO.
Ill go in order of my largest holdings, CCO/CCJ, URA, EFR/UUUU, and DNN/DML
My only nuclear stock is Cameco CCO from Canada. Sell the uranium.
Thoughts on CCO? Does this baby still have room to run or is the nuclear party done?
CCO/CCJ let's gooooo!
Absolutely, I'm in deep on UUUU, CCO, and URA Looking at DNN, any thoughts?
URA, CCO, UUUU, OKLO, LTBR, ASPI, DNN. ALL TO THE FUCKING MOON LETS GO 
“We are China's largest trade partner at around $500B.” A number that hasn’t moved in a decade. China can easily secure more food elsewhere, sure at higher prices but most US exports are corn and sou, which directly contribute to obesity. The CCO will spin this as fighting obesity: We hold none of the cards. They don’t need us because we have nothing they need. We need their manufacturing. And with Trump putting tariffs on and off at a whim, no one is going to want to build factories here. Why build factories here if you can’t price your inputs reliably?
LOL you libbies are funny. I make an even keel cool 150 k a year as a certified CCO crane operator, I voted for Dems once. But Trump is a much better choice IMO. Dems have lost thier way dude. Enjoy your Kroger!
Any uranium plays with penny stocks? I'm mostly in URA, CCO, UUUU, and DNN. lost some money with PEGA on the tsxv. Thanks
Uranium should do well, but I have never been a big fan of DNN. Look at the long term chart. Far underperforms a stock like CCO.TO. Denison is poorly run and lives off of being a "cheap" listing for uranium bulls to support. Rather than actually developing a profitable and growing business with producing uranium assets. Management is there just to collect an easy paycheck IMO.
How much money under the table is the CCO funding deepseek is the real question? people really are dumb enough to believe data from Chinese companies
CCO. Dipping right now, but I'm holding long term.
QSI's making big moves in protein sequencing tech. Their [Platinum instrument was the first benchtop sequencer with single-molecule resolution](https://beyondspx.com/article/quantum-si-qsi-pioneering-the-future-of-protein-sequencing), and they just dropped a new library prep kit that cuts prep time to under 2 hours. Plus they [brought in Todd Bennett as CCO](https://beyondspx.com/article/quantum-si-qsi-pioneering-the-future-of-protein-sequencing) - dude's got 30 years in life sciences and is already expanding their sales channels. But blind trading is risky af. They're still burning cash while ramping up commercialization. Look into the tech and financials before yoloing. This isn't a meme stock - it's a legit biotech play that needs proper DD.
u/ADropinInfinity I watched the middle east conference, CCO of Archer said there they struck a deal with Emirates leadership to have Archer fly their aircraft there in 2025, I think there is a chance it hits 9-10 today which is 200-300k for your pockets.
There's 3 ways 1) Reverse split to let's say 1 to 4 wich would get them to 2 dollars 2) Make enough money to buy back stocks to drive up price 3) Just plug along and keep making money and hope investors are interested. 3 is the best option obviously. Now in my opinion, before the conference call the 11th I would not have known. It could go either way. Reverse splits suck. But after the 11th, they are in talks with a distributor for the VA. They also have the naval hospital in Guam. And they have a cardiac surgery fda approval pending along with a CE mark from the EU which would trigger a distributor to make a lump sum prepayment. The forecast is in December. My advice would be to go to the investor relations section of Beyond Air Inc's website and sign up for updates. They send their press releases, sec filing and so on. As far as I can tell from the shareholders meeting, a Reverse split is not on the table as of yet. They also got some big name investors to go in. I can't tell you to get in or not. But for me, I'm not worried about it delisting. Not to plug my channel. But I do have a YouTube channel devoted to my investment and there you can hear earnings calls and other news. I try to be as unbiased as possible. (Of course harder said then done) the name is xairinvestor. I recently posted the earnings call from the 11th. My biggest thing is their CEO and CCO are both experienced in being in such a precarious position and pulling off a win. It definitely is a razors edge. Mid February is the delisting deadline.
took my 4000% MSTR gain, maxed out my First Home Savings Account and put the rest back into MSTR calls. Got shares of CCO (cameco) & PRL (propel holdings)
CCO. 28% of the world's raw uranium.
NLR holds SMR, CCO (U.S. CCJ) and OKLO so not a bad choice.
In a volatile market like uranium, I prefer to go for established companies with a greater moat and dominance. This will reduce risk although the premiums on eps is higher. For example: Cameco (CA:CCO/ US:CCJ) is a solid leader in the uranium world, thanks to its large, high-quality reserves and its integrated setup that covers everything from mining to fuel production. One of its big advantages is locking in long-term contracts, usually around 5-10 years, which keeps cash flow steady and shields it from the ups and downs in uranium prices. This is a common practice for major players, though even smaller producers go for similar deals to keep things stable. They uranium to 37 nuclear utilities worldwide, with 58% of its volume delivered to the Americas, 16% to Asia, and 26% to Europe. The company’s five largest customers account for 62% of its commitments.  Globally, the United States, China, and France are the leading consumers of uranium, collectively representing approximately 58% of the global demand.  With YoY demand increasing, I suspect uranium is bullish in the long run as more reactors (both traditional and modular) are going online next the next 5-10 years.
> ROIC is misleading when you work with early stage tech development because once you DO manage to commercialize the tech profitably then ROIC normalizes. This is a really interesting perspective. I think I've become too hyper-fixated on the bean-counting aspect of things (ROIC, P/E, EPS), which doesn't necessarily apply for developing companies. Also 200% agreed with the Tesla perspective. Are there any Uranium ETF's you've been looking at? I quickly glanced at URA (Global X Uranium ETF) and NLR (Van Eck's ETF); I like the companies in URA more, but the balance is so off. 24% of the ETF being one stock (CCO: Cameco Energy) is a bit too much to me.
CCO = Clear Channel Outdoor Holdings
ARTG CCO PNG and E is why...
Canadian companies like ARTG TEC CCO PNG and BDT or... just buy a S&P index ETF and make 20-30% a year but like... I'd prefer 100+% of my money a year not 30%
What the reply error said but don't dollar cost average just on these specific stocks/etfs. They do a good 25-30% all year long not matter when you check ytd. So 30% per year after 10 years that 300% your investment and its the safest play you can make getting into the market. Personally I I vest in Canada and buy ARTG TEC E PNG and CCO at the moment thats... into the thousands of percentage gains in 10 years.
Was looking at CCO today on tsx. Canadian uranium company and their PE is 130 Rn. Spiked big time from this news
Positions. 70k@CAD 57 CCO
Borrow yuan, buy Chinese stocks, CCO print money, Chinese stocks go up, you return your loan, and make a lot of money. Question: how do you borrow yuan
Cameco trades as CCO (TSX) in Canada
The iar... As In the Ex as Investment Advisor Rep would be sanctioned. And, if he's doing it to her, he's doing it to other employees and participants and it's still illegal. If she has an attorney she and her attorney could make these violations known to him as the CCO should make voluntary corrective actions before they get escalated with provides her with some Leverage
Hi, A couple companies actif in the construction of nuclear reactors: Cameco (CCJ/CCO) and Nuscale Power Corp (SMR) And in the meantime: Before that announcement of Kazakhstan about the 17% cut in projected uranium production for 2025, **the global uranium supply problem** looked like this: https://preview.redd.it/1yvayjcdwatd1.jpeg?width=534&format=pjpg&auto=webp&s=aeefd8bc19aac06f634d894dff749909f22f96f3 Source: Cameco using data from UxC, 1 of 2 global sector consultants for all uranium producers and uranium consumers in world **A couple uranium sector ETF's**: * Sprott Uranium Miners ETF (URNM): 100% invested in the uranium sector * Global X Uranium index ETF (HURA): 100% invested in the uranium sector * Sprott Junior Uranium Miners ETF (URNJ): 100% invested in the junior uranium sector * Global X Uranium ETF (URA): 70% invested in the uranium sector * Betashares Global Uranium ETF (URNM on ASX): 100% invested in the junior uranium sector **This isn't financial advice. Please do your own due diligence before investing** Cheers
CCO and DNN Largest and biggest players in Canada. Both will be supplying uranium to the Saskatchewan government for their new proposed nuclear reactor. 🤫
It’s not. She’s an investor, apparently has done well with concentrated/yoloed investments. Long story short, old CEO (founder) continually mismanaged company for 20 years, had friends on board. Finally a shake up; managed to kick out founder (who is still making some moves to regain influence) and hire the CCO from VMware. It gets interesting because LPSN mainly had customer relations issues, this new CEO has that experience and already took two others from the customer team at VMware to create a retention officer and fill the customer service leader. So now three top customer relations from VMware at the head of LPSN, which was suffering from mismanagement and no communication with customers. And they have divested from the founder’s latest cash-waster, and refinanced their debt which has apparently gained enough confidence for analysts to upgrade, and CEO claims customers are now confident they can sign long-term contracts with company. Didn’t post a single number about recurring revenue, debt, market size, I know. But maybe take a look
I'm in on CCO.TO & FLR for the same reasons. Cameco has one of, if the largest, uranium mines in the world. Fluor is the majority owner of Nuscale; the only SMR startup with design approval from the US Nuclear Regulatory Commission.
PTON; your CFO, CCO and CSCO selling off their stocks 3 days before the earnings report is usually not a good sign 
Your CCO and CSCO selling off their stocks 3 days before the earnings report is usually not a good sign 
This is exactly where I started. $2000 at $1.31. I averaged down to $0.75 by adding another $2000. I sold at $0.37 and lost approximately $2000. I might buy back in at some point, but the uranium market took a huge hit in the last couple of weeks. So even if the get good results from the new project, it likely wont help much until stocks like Cameco (CCO.TO) and Denison mines (DML.TO) start improving.
I have thought about this. CCO Raja is out. Big problems though is absolutely terrible share dilution (look at the count YoY) and no incentive or rewards to shareholders. They built two shiny new buildings in DFW when they should be cost cutting and trying to fix their debt. It is jaw dropping air travel is at ATHs but the stock is near Covid lows where **no flights were in the skies.**
I worked at the MacArthur river mine for 4 years and then the Key Lake mill for another 8 yrs. I was still at Mac Riv the day Fukashima happened, anyone with 1/2 a brain could see the writing on the wall, the stock was going to crater. Then the massive layoffs that followed and the mothballing of the mine and mill for a few years of “care and maintenance” mode. The boys just signed a new CBA with the company after being out of scope since 2022, new contract ends at the end of 2024 i was told. Anyways, clear sailing ahead for CCO, solid play.
Why not own HURA instead, or at least include CCJ/CCO to the stock picks? Just curious.
Counterpoints: 1) Both the CFO and CCO have sold off sizable amounts of their holdings this month (40% and 70%, respectively); 2) HIMS is able to sell compounded semaglutide (weight loss) because 3 of the dose sizes are currently in shortage. This could end at any moment (unlike their other product lines), reversing a sales projection that's already reflected in the price. Regardless, ad conversion has stayed consistent as revenue has grown (they spend 44% of revenue on advertising) and their SG&A also seems to grow proportionally to revenue. So they can be expected to always do 80% gross margins, with another 44% ads and 30% SG&A. So at a $1B, they'll do $800M gross profit against ad costs of $440M and another $300M in SG&A. That leaves $60M net, which has covered other costs ($66M last year). So at $2B in revenue they can maybe eek out $60M in earnings, which means that even if you assume they double revenue in the next year they're currently priced at 80x some very rosy future earnings. I'm sure people will buy this stock, so it's doesn't matter. But the only economic winners with their business are the advertisers (for instance, RDDT).
My uncle in law is CCO of a publicly listed company. I just for shits and giggles did a F/A on the stock and noticed him and the CEO both sold (him 90% of shares and ceo like 40%) only months before a 50% stock drop from losing their govt. Contract (75% of revenue) in the following earnings report
If you see the note from the ER, including kicking the CCO out, it’s all about strategic failures. They miss the point: flying AAL is terrible. I’m stuck with them for the most part and wished I could fly DL or UA.
>Sure, there’s certainly a stigma, an age-old stigma, that’s been associated with cannabis for a very long time. And the most important way we can change that stigma is by educating people and showing the professionalism and the normalization of buying cannabis,” said Jason Erkes, CCO of Cresco Labs. >Cresco Labs in Yellow Springs planted almost 1,000 cannabis plants using sophisticated led lights to mimic the four seasons, and high tech cooling and humidification systems to control every element in the plants’ environment. Even with all of the extensive machinery, staff aims to maintain a “homegrown” energy with their production process. >“The products here are grown by Ohioans. They are tested in the state of Ohio, they are packaged and child-safety sealed and delivered to Ohio dispensaries, and sold at Ohio dispensaries,” Erkes said. “So I think that people that are going into the stores can have a peace of mind that there’s confidence in the product they’re buying.” >With the recent rule changes in the state legislature, Cresco Labs foresees many new consumers coming to purchase cannabis in the near future, and they certainly want to be prepared. >“People are generally excited about this happening,” Erkes said. “There will be people lined up outside the stores who want to be part of that first day, they want to partake in that first sale, and be part of the excitement.” >After approved new licensing rules for dispensaries in Ohio, recreational marijuana could become available for adult consumers by mid-June.
I held CCO from $20 to $50-$60 and now my uranium position is 100% in HURA.TO
I'm thinking demand for uranium will grow significantly. Cameco CCO.TO seems to have a bright future ahead.